Close Menu

NEW YORK (GenomeWeb) — PrediLife said today that it has signed on the Institut Curie to perform the genetic analysis portion of its MammoRisk breast cancer risk assay.

MammoRisk — used in conjunction with mammograms — is designed to determine breast cancer risk using a patient's age, breast density, family history, and breast biopsy history, as well as a polygenic score based on the analysis of disease-linked genetic variations from a saliva sample.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.